Alnylam (ALNY) Q1 2026: TTR Franchise Surges 153% YoY, Propelling $1B+ Quarterly Milestone
Alnylam’s Q1 marked a pivotal inflection as TTR franchise revenues soared 153% year-over-year, driving the company’s first-ever $1B quarter. This performance was anchored by robust U.S. and international execution, resilient rare disease growth, and a deepening pipeline. Management reiterated full-year guidance and signaled accelerating momentum into 2026, with expanding prescriber base and new launches offsetting pricing headwinds abroad.
Summary
- TTR Franchise Expansion: Physician adoption and prescriber base growth are accelerating first-line use and durable revenue streams.
- Pipeline and Platform Scale: Over 25 clinical programs signal a multi-billion opportunity beyond TTR with near-term readouts ahead.
- Margin and Mix Dynamics: Royalty step-ups and ex-U.S. pricing resets are pressuring gross margin, but top-line momentum and disciplined R&D investment support long-term growth.
Performance Analysis
Alnylam delivered its first-ever $1B+ quarter, with total net product revenue up 121% year-over-year, driven by the TTR (transthyretin-mediated amyloidosis, a rare protein misfolding disease) franchise. The TTR business, now contributing the vast majority of total revenue, saw U.S. sales jump over 230% YoY and 9% sequentially, even as Q1 faced fewer shipping weeks and insurance reauthorization headwinds.
The rare disease portfolio also showed resilience, up 15% YoY, though higher gross-to-net deductions partially offset demand gains. International TTR revenue, while down sequentially due to anticipated German price resets, outperformed expectations thanks to strong launches in Japan and ongoing expansion in Europe. Gross margin compressed by 5 points YoY to 80%, reflecting higher Sanofi royalties as Ambutra (RNAi therapy for ATTR-CM) sales accelerate. Operating income more than quadrupled, underscoring the leverage in Alnylam’s model as scale builds.
- TTR Growth Engine: Global TTR revenues reached $910M, with U.S. momentum overcoming seasonal and inventory headwinds.
- Rare Disease Stability: Rare disease net revenue hit $126M, maintaining steady contribution amid portfolio focus.
- Margin Compression: Royalty rate step-ups and ex-U.S. price adjustments are offset by top-line growth and pipeline investment.
Alnylam’s disciplined investment in R&D (up 39% YoY) and SG&A (up 36%) reflects a scaling organization, with management reiterating full-year guidance and confidence in accelerating TTR growth through 2026.
Executive Commentary
"Our leadership in PTR amyloidosis was on display having achieved over $900 million in total net revenues from Vutra and Onpatro combined... The more than $1 billion in combined net product revenues generated in Q1 marks Alnylam's first quarter exceeding the threshold in our history, an important milestone."
Yvonne Greenstreet, Chief Executive Officer
"Gross margin on product sales was 80% for the first quarter, representing a 5% decrease compared with Q1 last year. The decrease in margin was primarily driven by increased royalties on Ambutra as higher revenues in 2026 resulted in an increase in the average royalty rate payable to Sanofi compared with the same period last year."
Jeff Poulton, Chief Financial Officer
Strategic Positioning
1. TTR Franchise Leadership and Launch Dynamics
Alnylam’s TTR franchise is now the company’s primary growth engine, with Ambutra driving rapid physician adoption and expanding first-line use. Management highlighted a prescriber base expansion of over 1,200 new U.S. physicians since last March. Experience with Ambutra leads to deeper, more durable prescribing, and adherence rates above 90% support recurring revenue. International launches, especially in Japan and Europe, are offsetting price resets in Germany, with the overall mix shift expected to become net accretive as volume grows.
2. Pipeline Depth and Platform Leverage
The company’s pipeline spans over 25 clinical programs, targeting rare, specialty, and prevalent indications. Near-term catalysts include phase two and three readouts in bleeding disorders, Huntington’s disease, and obesity, while next-gen TTR silencer Nucresiran progresses in phase three with enrollment expanded to 1,750 patients to safeguard against low event rates. Management reiterated its ambition to deliver at least two new blockbuster medicines beyond TTR by 2030.
3. Margin and Cash Flow Management
Gross margin headwinds from rising royalty rates and international price resets are being actively managed, with scale-driven operating leverage evident in quadrupled operating income. Cash and equivalents rose to $3B, reflecting strong operating performance and prudent capital allocation.
4. Commercial Execution and Market Access
Alnylam’s access strategy has secured over 90% of U.S. patients with first-line coverage and minimal out-of-pocket costs, supporting broad adoption. The company’s AI-enabled partnerships are improving diagnosis rates and patient identification, addressing significant underdiagnosis in ATTR-CM.
5. Competitive and Regulatory Positioning
Upcoming competitor readouts (e.g., CardioTransform) are viewed as class-validating rather than disruptive, with Alnylam’s established first-line access, combination labeling, and robust data package positioning it to sustain leadership regardless of generic stabilizer entry or new silencers.
Key Considerations
Alnylam’s Q1 demonstrated robust execution across commercial, operational, and R&D fronts, but investors should weigh several evolving dynamics as the year progresses.
Key Considerations:
- Physician Adoption Curve: First-line utilization and prescriber base expansion are critical for sustaining TTR revenue momentum and offsetting second-line normalization.
- International Price Reset Impact: German and other ex-U.S. pricing adjustments will pressure near-term gross margin, but mix shift and volume growth are expected to drive net gains over time.
- Pipeline Execution: Timely delivery of phase two and three readouts, especially for Nucresiran and bleeding disorders, is essential for platform validation and future revenue streams.
- Royalty and Margin Management: Rising Sanofi royalty rates on Ambutra require ongoing margin discipline and may cap near-term upside, even as top-line accelerates.
Risks
Key risks include gross margin compression from royalty step-ups, potential delays or negative outcomes in pivotal pipeline trials, and pricing or access challenges as new competitors enter the TTR market. Ex-U.S. pricing resets, particularly in Germany, could weigh on international revenue and profitability in the near term. Additionally, evolving payer dynamics and generic stabilizer entry may shift the treatment landscape, demanding agile commercial execution.
Forward Outlook
For Q2 and the remainder of 2026, Alnylam guided to:
- Accelerated quarter-over-quarter TTR revenue growth, both in the U.S. and internationally
- Full-year TTR product sales between $4.4B and $4.7B
Management reiterated guidance and highlighted:
- Continued confidence in Ambutra’s launch trajectory and prescriber expansion
- Anticipated net positive contribution from ex-U.S. markets as mix shift takes hold
Takeaways
Alnylam’s Q1 2026 results reinforce its leadership in RNAi therapeutics and the ATTR-CM market, with the TTR franchise now a multi-billion dollar annualized business. The company’s platform, pipeline, and commercial reach provide a foundation for long-term growth, but margin discipline and pipeline execution remain critical watchpoints.
- TTR Franchise Outperformance: Physician adoption and adherence trends support durable revenue growth, even as payer and pricing dynamics evolve.
- Pipeline Readouts Loom: Upcoming data in bleeding disorders, Huntington’s, and next-gen TTR silencers will be pivotal for platform expansion and investor confidence.
- Margin and Mix in Focus: Investors should monitor gross margin trends and international pricing resets, as well as the impact of royalty step-ups on profitability.
Conclusion
Alnylam’s first-ever $1B quarter marks a strategic milestone, with robust TTR franchise growth, disciplined execution, and a deep pipeline positioning the company for continued outperformance. Margin pressures and competitive dynamics warrant close attention, but the company’s innovation engine and commercial foundation remain clear strengths.
Industry Read-Through
Alnylam’s execution signals a broadening opportunity for RNAi therapeutics, with real-world adherence, payer access, and prescriber expansion driving durable adoption. The ATTR-CM market remains significantly underdiagnosed, suggesting continued growth runway for both Alnylam and class competitors. However, royalty step-ups and ex-U.S. pricing resets highlight the importance of margin management as RNAi therapies move from rare to more prevalent indications. For the broader biotech sector, Alnylam’s modular innovation model and disciplined commercial scale-up offer a template for translating platform science into sustained financial performance.